First-line management of metastatic urothelial cancer: Current and future perspectives after the EV-302 and CcheckMate-901 studies
Keywords: 
Molecular characterization
Paradigm shift
Sequence of treatments
Personalized treatment
Immune therapy
Issue Date: 
2023
Publisher: 
Elsevier
ISSN: 
1938-0682
Citation: 
Fenor-de-la-Maza, M.D. (Maria Dolores); Villacampa, G. (Guillermo); Miñana, B. (Bernardino); et al. "First-line management of metastatic urothelial cancer: Current and future perspectives after the EV-302 and CcheckMate-901 studies". Clinical Genitourinary Cancer. S1558-7673 (23), 2023, 00267-7
Abstract
The standard of care for the first-line management of metastatic urothelial carcinoma has been recently challenged, with the combination of pembrolizumab and enfortumab vedotin (P-EV) strongly arising as a practice-changing option from classical platinum-based chemotherapies. With this paradigm shift on the horizon new questions, including the most suitable second line of treatment for these patients, and the role that the molecular characterization of these tumours will have when selecting these therapies will inevitably arise. Furthermore, after the negative results of the Keynote 361 and IMvigor 130 trials, the combination of nivolumab with platinum-based chemotherapy followed by nivolumab maintenance (Nivo GC-Nivo) has also shown positive results when compared with chemotherapy alone. Translational studies at a molecular, cellular, and functional level will be key to better explain these discordant results. In this Current Perspective, we discuss the potential impact of these results in clinical practice and propose specific guidance for prospective translational research.

Files in This Item:
File
Guillermo_first.pdf
Description
Size
193.46 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.